Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes



Status:Active, not recruiting
Conditions:Obesity Weight Loss, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:21 - 65
Updated:2/17/2018
Start Date:January 2010
End Date:March 2018

Use our guide to learn which trials are right for you!

Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D)

There is substantial clinical evidence regarding the safety and efficacy of currently
practiced bariatric surgical techniques to improve metabolic control and/or resolve type 2
diabetes (T2DM) in clinically severe obese patients (class 3 obesity). Evidence suggests such
procedures have greater effects on insulin secretion and insulin action than that expected
from weight loss alone, which has led to the recent claim that such procedures may be useful
as a primary treatment for T2DM in the moderately obese population. Concurrently, there have
also been substantial advances in the non-surgical medical management of T2DM. As a result,
the best treatment algorithm for T2DM patients with class 1 & 2 obesity is increasingly
controversial. This trial investigates the utility of currently practiced and available
bariatric surgical procedures as compared with multidisciplinary intensive medical and weight
management for the treatment of T2DM with class 1 and 2 obesity.


Inclusion Criteria:

- Potential participants will be those with T2DM, with a diagnosis of diabetes of at
least one year in duration,

- BMI 30-45 kg/m2 for the LAGB compared to intensive medical weight and diabetes
management and BMI 30-42 kg/m2 for LRYGB compared to intensive medical weight and
diabetes management,

- Age 21-65 years,

- With a strong desire for substantial weight loss, who are free from active
cardiovascular or other diseases that would render them unable to partake in a
structured exercise program or to undergo a bariatric surgical procedure, and who are
committed to life long medical and nutritional follow up.

Exclusion Criteria:

- Detectable levels of GAD antibody or a history of diabetic ketoacidosis or
uncontrolled T2DM (consistent fasting blood glucose >200 mg/dl or HbA1c above twice
normal);

- Previous gastrointestinal surgery, inflammatory bowel disease, esophageal diseases
including severe intractable esophagitis, Barrett's Disease, esophageal dysmotility or
other impaired gastric motility (gastroparesis), or hiatal hernia >3 cm in size,
chronic or acute bleeding conditions including peptic ulcer disease, portal
hypertension (gastric or esophageal varices), chronic pancreatitis, or cirrhosis of
the liver;

- Malignant or debilitating medical conditions, severe cardiopulmonary disease including
uncontrolled hypertension (repeated systolic measures >160 or diastolic > 95 mm Hg on
more than one day), unstable angina pectoris, recent myocardial infarction within 6
months, history of coronary artery bypass surgery or angioplasty, congestive heart
failure, arrhythmia, stroke or transient ischemic attacks, urinary albumin excretion
>300 mcg/mg creatinine and/or serum creatinine >1.5 mg/dL (permitting safety of
increased dietary protein intake),

- Any endocrine disorder other than T2DM or thyroid disease which is stable on
replacement therapy, including Cushing's syndrome;

- Any previous history of eating disorders, history of drug and/or alcohol abuse within
2 years of the screening visit, history of impaired mental status by DSM-IV
(Diagnostic and Statistical Manual, 4th Edition) criteria and including, but not
limited to active substance abuse, a history of schizophrenia, borderline personality
disorder, uncontrolled depression, suicidal attempts within the past two years or
current suicidal tendencies or ideations.

- Subjects will be excluded if there is a history of significant weight loss (>3%)
within the previous 3 months or participation in alternate medically supervised
exercise or weight reduction program within the previous 3 months, or with use of
prescription or over the counter weight reduction medications or supplements within
one month of the Screening Visit and for the duration of study participation.

- Women who are lactating, planning pregnancy, or unwilling to use contraception during
the course of the trial.
We found this trial at
2
sites
One Joslin Place
Boston, Massachusetts 02215
617-309-2400
Joslin Diabetes Center Joslin Diabetes Center, located in Boston, Massachusetts, is the world's largest diabetes...
?
mi
from
Boston, MA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials